Mai Honda-Kitahara
Overview
Explore the profile of Mai Honda-Kitahara including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
233
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kawauchi D, Ohno M, Sugino H, Ito K, Fuse K, Yoshida A, et al.
J Neurosurg Case Lessons
. 2025 Mar;
9(9).
PMID: 40030156
Background: Glioblastoma (GBM) is known for its significant intratumoral heterogeneity, making biopsies susceptible to underdiagnosis if samples are taken from less malignant regions. [18F]Fluciclovine, a novel PET tracer, has demonstrated...
2.
Ozeki Y, Honda-Kitahara M, Yanagisawa S, Takahashi M, Ohno M, Miyakita Y, et al.
Jpn J Clin Oncol
. 2024 Dec;
55(2):106-112.
PMID: 39660448
Background: Isocitrate dehydrogenase-mutant astrocytoma without cyclin-dependent kinase inhibitor 2A/B (CDKN2A/B) homozygous deletion typically follows a slow clinical course. However, some cases show early progression on magnetic resonance imaging, and these...
3.
Sugino H, Satomi K, Mori T, Mukai Y, Honda-Kitahara M, Matsushita Y, et al.
Brain Tumor Pathol
. 2023 Feb;
40(2):133-141.
PMID: 36811792
In the World Health Organization tumor classification (fifth edition), central nervous system (CNS) tumors with BCOR internal tandem duplications have been recognized as a new tumor type. Some recent studies...
4.
Kawauchi D, Ohno M, Honda-Kitahara M, Miyakita Y, Takahashi M, Yanagisawa S, et al.
BMC Neurol
. 2023 Jan;
23(1):9.
PMID: 36609238
Background: Glioblastoma (GBM) infrequently recurs in the infratentorial region. Such Infratentorial recurrence (ITR) has some clinically unique characteristics, such as presenting unspecific symptoms and providing patients a chance to receive...
5.
Nagane M, Ichimura K, Onuki R, Narushima D, Honda-Kitahara M, Satomi K, et al.
Cancers (Basel)
. 2022 Nov;
14(22).
PMID: 36428615
We evaluated the efficacy and safety of bevacizumab beyond progression (BBP) in Japanese patients with newly diagnosed glioblastoma and explored predictors of response to bevacizumab. This phase II study evaluated...
6.
Hosoya T, Takahashi M, Davey C, Sese J, Honda-Kitahara M, Miyakita Y, et al.
Biomolecules
. 2022 Oct;
12(10).
PMID: 36291588
The aim of the present study was to determine which individual or combined CpG sites among O-methylguanine DNA methyltransferase CpG 74-89 in glioblastoma mainly affects the response to temozolomide resulting...
7.
Yamada S, Tanikawa M, Shibata H, Honda-Kitahara M, Nakano Y, Satomi K, et al.
Neuropathology
. 2022 Sep;
42(6):512-518.
PMID: 36071620
Diffuse leptomeningeal glioneuronal tumor (DLGNT) is a rare glioneuronal neoplasm newly included in the 2016 World Health Organization Classification of Tumors of the Central Nervous System. Owing to the wide...
8.
Satomi K, Yoshida A, Matsushita Y, Sugino H, Fujimoto K, Honda-Kitahara M, et al.
Brain Tumor Pathol
. 2022 Jul;
39(4):210-217.
PMID: 35902443
The current World Health Organization classification of diffuse astrocytic and oligodendroglial tumors requires the examination of isocitrate dehydrogenase 1 (IDH1) or IDH2 mutations. Conventional analysis tools, including Sanger DNA sequencing...
9.
Central nervous system sarcoma with ATXN1::DUX4 fusion expands the concept of CIC-rearranged sarcoma
Satomi K, Ohno M, Kubo T, Honda-Kitahara M, Matsushita Y, Ichimura K, et al.
Genes Chromosomes Cancer
. 2022 Jun;
61(11):683-688.
PMID: 35715887
CIC-rearranged sarcoma is a high-grade sarcoma, most often harboring CIC::DUX4 fusion, and is characterized by a distinct round cell histology, co-expression of ETV4 and WT1, and a specific DNA methylation...
10.
Hosoya T, Takahashi M, Honda-Kitahara M, Miyakita Y, Ohno M, Yanagisawa S, et al.
J Neurooncol
. 2022 Apr;
157(3):561-571.
PMID: 35397757
Purpose: Although the usefulness of O-methylguanine DNA methyltransferase (MGMT) promoter methylation analysis for predicting response to chemoradiotherapy and the prognosis of patients with glioblastoma has been widely reported, there is...